MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Altman Z2-Score: 8.00 (As of Jul. 05, 2026) — Near Median


IST:MEDTR MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
82 GF Score
Price ₺28.86
GF Value ₺43.61
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score?

MEDITERA TIBBI MALZEMENAYI VE TICARET AS IST:MEDTR -1.30% 82 Altman Z2-Score is 8.00 as of Jul. 05, 2026, which is 1% above its 10-year median of 7.90. GuruFocus rates IST:MEDTR with a GF Score™ of 82/100 and a GF Value™ of ₺43.61 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 846 Medical Devices & Instruments companies, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks better than 76.95% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a Altman Z2-Score of 8.00, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score or its related term are showing as below:

IST:MEDTR' s Altman Z2-Score Range Over the Past 10 Years
Min: 7.01   Med: 7.9   Max: 11.93
Current: 8

During the past 8 years, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's highest Altman Z2-Score was 11.93. The lowest was 7.01. And the median was 7.90.


MEDITERA TIBBI MALZEMENAYI VE TICARET AS  (IST:MEDTR) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score Related Terms


MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score Chart

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 11.93 9.15 7.46 7.57 7.59

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 7.31 7.01 7.59 8.00

IST:MEDTR vs ABT, SYK, MDT: Altman Z2-Score Comparison

For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score falls into.


IST:MEDTR
82GF Score
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3584+3.26*0.1715+6.72*-0.0002+1.05*4.8473
=8.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ₺3,820 Mil.
Total Current Assets was ₺1,900 Mil.
Total Current Liabilities was ₺531 Mil.
Retained Earnings was ₺655 Mil.
Pre-Tax Income was -65.587 + -26.104 + 48.431 + 5.609 = ₺-38 Mil.
Interest Expense was -11.249 + -15.321 + -6.452 + -3.902 = ₺-37 Mil.
Total Liabilities was ₺649 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1899.712 - 530.714)/3820.198
=0.3584

X2=Retained Earnings/Total Assets
=655.215/3820.198
=0.1715

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-37.651 - -36.924)/3820.198
=-0.0002

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3143.932 - 0)/648.6
=4.8473

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a Altman Z2-Score of 8.00 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 8.00 mean?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Altman Z2-Score of 8.00 as of Jul. 05, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. This is near median its historical median of 7.90. Over the past decade, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score has ranged from 7.01 to 11.93. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #195 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 23%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Altman Z2-Score of 8.00 is near median its 10-year median of 7.90. Over the past 10 years, this metric has ranged from a low of 7.01 to a high of 11.93. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 8.00 is 129.9% above this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #195 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #195 out of 846 companies for Altman Z2-Score. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the top 23% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.48. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 8.00 is 129.9% above this benchmark. Historically, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's own Altman Z2-Score has ranged from 7.01 to 11.93 over the past decade. While the company's 10-year median is 7.90 vs. the industry median of 3.48, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Altman Z2-Score of 8.00 is 129.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Altman Z2-Score is 8.00, which is near median its own 10-year median of 7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺43.61, compared to a current price of ₺28.86 — trading 33.8% below its estimated fair value. The current Altman Z2-Score is 8.00, which is near median its 10-year median of 7.90 and 129.9% above the Medical Devices & Instruments industry median of 3.48. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Altman Z2-Score is 8.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?

Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued. The current stock price of ₺28.86 is trading 33.8% below its estimated GF Value™ of ₺43.61. GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.

Key valuation signals for IST:MEDTR:

  • Altman Z2-Score: 8.00 (near median its 10-year median of 7.90)
  • GF Value™: ₺43.61 vs. price of ₺28.86 (33.8% below fair value)
  • GF Score™: 82/100 with 5 warning signs
  • Industry Position: 129.9% above the Medical Devices & Instruments median (#195 of 846)

No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description

Address Sokak No: 29 Tire Organize Sanayi, Ibni Melek OSB Mahallesi, TOSBI Yol 4, Bolgesi Tire, Izmir, TUR, 35900
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
82GF Score

Get the complete analysis for IST:MEDTR

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺28.86
Price
₺43.61
GF Value